Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Straks terug een ingevallen pudding ;-) we kennen het ondertussen.
Geen nieuws schreef op 11 december 2018 13:57 :
Ik ben blij te weten dat monitor voor Kempen werkt !
Dan maar uit dit forum zou ik zeggen !
Zouden ze beter eens met jou doen. Al de zoveelste (laatste) waarschuwing te pakken voor je infantiel gedrag en leert er nog steeds niet van.
Forum Addict schreef op 11 december 2018 14:27 :
[...]
Wat zal jij spijt krijgen.
dat zou erg goed kunnen maar nooit zoveel spijt als van ze vast te houden van 1.2 tot 0.79
Wat dacht je monitor, ik ga een uurtje typen ! Sorry, maar we gaan nu eerst de 0.90 opzoeken ! En dat hoeft niet direct !
Geen nieuws schreef op 11 december 2018 14:31 :
maar we gaan nu eerst de 0.90 opzoeken !
Ik hoop het van harte. Liever de 1.20 regionen, dat zou het nog beter maken. Maargoed ik weet ook wel dat sprookjes niet bestaan.
De Monitor schreef op 11 december 2018 14:31 :
[...]
Zouden ze beter eens met jou doen. Al de zoveelste (laatste) waarschuwing te pakken voor je infantiel gedrag en leert er nog steeds niet van.
infantiel gedrag ... toe maar jij durft??
dimitri00 schreef op 11 december 2018 14:31 :
[...]
dat zou erg goed kunnen
maar nooit zoveel spijt als van ze vast te houden van 1.2 tot 0.79
Je bent te vroeg met verkopenprntscr.com/ltjqyw
Forum Addict schreef op 11 december 2018 14:39 :
[...]
Je bent te vroeg met verkopen
prntscr.com/ltjqyw idd iets te vroeg zo blijkt het hangt er vooral vanaf hoe ver het terugvalt
dimitri00 schreef op 11 december 2018 14:41 :
[...]
idd iets te vroeg zo blijkt
het hangt er vooral vanaf hoe ver het terugvalt
Waarom zou de koers terugvallen, waar baseer je dat op?
niet verkopen onder de € 1,20
Forum Addict schreef op 11 december 2018 14:44 :
[...]
Waarom zou de koers terugvallen, waar baseer je dat op?
Omdat het dat de laatse paar keer met een stijging van +4% deed en hard ook. Ik hou ze vast want ik ben er weer zo eentje die dan weer de boot mist als hij wel door stijgt...
3 € Pharming schreef op 11 december 2018 14:45 :
niet verkopen onder de € 1,20
Die uitspraak is gedaan door Sijmen toen de koers zo rond de 80 cent stond. Dus had je beter naar hem geluisterd door te verkopen boven 1.20. Had je nu flink wat winst in je zakken (of geen verlies).
Forum Addict schreef op 11 december 2018 14:44 :
[...]
Waarom zou de koers terugvallen, waar baseer je dat op?
de laatste 20 oplevingen
Pharming nu opnieuw boven de € 0,80. Het geschaaf kan weer beginnen...
Belegdbrood schreef op 11 december 2018 14:47 :
[...]
Omdat het dat de laatse paar keer met een stijging van +4% deed en hard ook. Ik hou ze vast want ik ben er weer zo eentje die dan weer de boot mist als hij wel door stijgt...
ja exact meestal heb ik ook prijs maar ik heb toch eens een deel verkocht nu
Komop, kopen kopen. Doe me een plezier en laat de koers nu eens lekker doorstijgen.
Belegdbrood schreef op 11 december 2018 14:47 :
[...]
Ik hou ze vast want ik ben er weer zo eentje die dan weer de boot mist als hij wel door stijgt...
En met u veel particulieren
Pharming : Dutch biotech Pharming plans to challenge big pharma in rare diseases 12/11/2018 | 10:27am CET The introduction of Shires preventive treatment for hereditary angioedema has shaken up the market for drugs for this rare disease. But the small Dutch biotech Pharming hopes that its older drug Ruconest will find a new niche in the disease, and beyond. Richard Staines spoke with CEO Sijmen de Vries to find out more. Although a very rare disease, hereditary angioedema (HAE) has been targeted by pharma companies searching for blockbuster revenues. Affecting between one in 10,000 to one in 50,000 people, symptoms include swelling in various parts of the body including hands, feet, face and airway, with patients often suffering excruciating abdominal pain, nausea, and vomiting. Despite the small patient pool, rare diseases are becoming increasingly important to pharma companies who can charge high premiums for drugs that will have little impact on overall health budgets in each country. But by getting rare disease drugs approved across the world companies like Shire have managed to build billion-dollar franchises in each niche. When Shire got its prophylactic treatment Takhzyro (lanadelumab) approved by the FDA earlier this year, it looked like everything was lined up in its favour in the market for HAE, with talk of blockbuster-level sales as the company prepares for its merger with Takeda early next year. But Dutch biotech Pharming says it wants to take on the might of Takeda and Shire with its already-approved Ruconest. Ruconest, a recombinant C1-Esterase inhibitor, is already FDA-approved for HAE attacks, and Pharmings CEO says the drug will still play a part once Takhzyro gains a foothold in the market. Breakthrough attacks Pharming estimates that around 25% of people on the new drug will have breakthrough attacks despite prophylactic treatment with Takhzyro, which is where Ruconest will find a niche. In an interview with pharmaphorum de Vries said he expected the drug to get significant market share by treating these patients who are still having attacks when prophylactic treatment has not worked. We see an opportunity arising where people need to have a reliable breakthrough attack medication, said de Vries, adding that the company is developing longer-acting formulations that could be more appealing to patients. Ruconest has not yet been approved for prophylaxis the FDA notably rejected an early filing from Pharming earlier this year but again de Vries is sticking to the story that this is a minor setback for the company. Pharming had not been expecting to file the drug as a prophylactic treatment from the phase 2 data it had gathered and had only submitted a dossier following a request from the FDA. The regulator was keen to see the drug approved in the indication and provide an alternative to Shires rival Cinryze from the same class, after shortages caused by problems with a manufacturing subcontractor last year. Despite the setback Pharming is continuing development, adding that the issue causing the FDA to reject the drug earlier this year will likely be addressed by these later trials. According to De Vries the focus is now on developing a more concentrated version of the drug and trials are planned for an intravenous, subcutaneous and intradermal formulations in prophylaxis. There is also a new intramuscular version under development for treatment of attacks. All of this was planned before the FDAs intervention and de Vries insists that development is progressing as had always been envisaged, although he could not give detail about timelines. We are back to executing on our plan making Ruconest a more convenient product, he said, Payers will begin to pay attention With the introduction of Takhzyro, payers will begin to become more concerned about their spend on drugs for HAE, the company said. Pharmings chief financial officer Robin Wright told pharmaphorum: If a significant number of patients go on to prophylaxis they will start to pay attention. The biotech says this could work in its favour as it has data in patients with severe disease, while Shire has to-date focused on patients with more moderate symptoms. Pharming is also eyeing other indications that are much bigger than HAE notably pre-eclampsia, for which there are few approved treatments. Another potential use for Ruconest is in acute kidney injury caused by contrast media in patients undergoing CT scans. The third biggest cause of acute renal injury occurring in hospitals, the condition known as contrast-induced nephropathy occurs in about 12% of cases. A small 75-patient phase 2 trial reported last month showed a statistically significant reduction in a biomarker associated with acute renal injury, and results were strongest in patients undergoing heart stent operations. The data supported further trials, Pharming said. Scaling up production with cow milk De Vries added that there are plans to scale up production of Ruconest, which is currently harvested from the milk of transgenic rabbits. Approval in further and larger indications would require milk from transgenic cows, and the technology is already in place to produce this virtually unlimited source of product. De Vries said: We are starting to milk cattle again and will probably start making a product from cow milk rather than rabbit milk. While Ruconest was the companys first drug on the market, it also has grand plans to disrupt the market in other rare diseases. CFO Wright noted the companys alpha-glucosidase molecule, which is designed as a replacement therapy for patients with the glycogen storage disorder Pompe disease. The molecule under development is much closer to the naturally occurring one than Sanofi/Genzymes already marketed Lumizyme (alglucosidase alfa), which could offer an alternative with fewer problems associated with immune reactions. If things go well, and the new drug proves less immunogenic in clinical trials, this will provide inroads to a market worth billions, according to Wright. In the meantime, the company is well placed to expand its operations financially as it is turning a small profit after managing to get Ruconest past regulators and established on the market over the last five years. De Vries said: We have turned from an ugly duckling to a company that has a product that we have commercialised ourselves and are profitable, this is unique. (c) 2018 Future Publishing Limited Quay House, The Ambury, Bath BA1 1UA. All rights reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspaperswww.marketscreener.com/PHARMING-GROUP...
ff wachten nog schreef op 11 december 2018 10:32 :
[...]Je vergeet voor het gemak de uitbetaalde dividenden van de verliezen af te trekken! Uit dit lijstje heb ik alleen Royal Dutch Shell met een huidig dividend rendement van 6,4% blijft dus netto een verlies van 2% over. De rest weet ik niet maar het is dus weer eens een sterk gekleurd lijstje van generlei waarde.
Het is toch wat he dat die TS dat durft andere dalers te noemen het is toch alleen PH die daalt over een zwarte bril gesproken.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)